Dietary Intervention Study in Adults with Newly Diagnosed Multiple Myeloma Receiving Standard DRVd Chemotherapy to Assess Treatment Response and Quality of Life

What this Trial Is About

Researchers are investigating whether a dietary intervention can influence treatment response and quality of life in people with newly diagnosed multiple myeloma undergoing standard induction chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone DRVd. The study aims to assess the effects of diet on quality of life, treatment response, and various disease, microbiome, and immune markers by having participants complete questionnaires and other evaluations. Participants are randomly assigned to one of two groups. One group receives usual care, which includes standard chemotherapy and phone calls every 4 weeks with study staff and a dietitian consultation at the end of chemotherapy. The other group receives an intervention with nutrition counseling and coaching, including biweekly dietitian calls for 12 weeks and high-fiber plant-based frozen meals shipped weekly for 12 weeks. Optional group sessions and text message reminders are also provided. Both groups complete dietary and quality of life surveys during the study. During the study, participants complete questionnaires measuring quality of life and dietary intake. Researchers will evaluate the rate of minimal residual disease negative complete response at one year and compare quality of life improvements between groups. Phone or video calls with dietitians and study staff support participant engagement. The study lasts through four 28-day chemotherapy cycles with follow-up assessments up to one year to monitor treatment and quality of life outcomes.

A Dietary Study for People With Multiple Myeloma